An independent, evidence-based review of Hallandale Pharmacy's LegitScript status, state board standing, FDA oversight, BBB record, and compounding accreditation. prepared by the HealthRX.com Editorial Team.
A detailed, data-driven look at Happy Head's compounded hair-loss treatment pricing over time, subscription model changes, complaint patterns, and how costs compare to FDA-approved alternatives.
An evidence-based, independent review of Henry Meds prescribing practices, compounded GLP-1 data signals, patient complaints, and regulatory standing. prepared by the HealthRX.com Editorial Team.
A detailed, independent review of Juniper Health's pricing history, plan changes, and cost trajectory for GLP-1 and weight-loss programs in Australia and the UK, with primary-source citations.
A data-driven look at how Keeps hair-loss subscription prices have shifted since 2018, what drives the cost changes, and how finasteride and minoxidil pricing compares to pharmacy and clinical benchmarks.
A data-driven breakdown of Musely's pricing history, subscription model changes, complaint patterns, and whether the telehealth skincare brand holds up to scrutiny.
A critical, data-driven look at Nurx pricing history, fee structures, complaint patterns, and how costs have shifted since 2015. prepared by the HealthRX.com Editorial Team.
An independent, evidence-based review of Nutrisense's medical leadership, credentials, regulatory standing, and CGM coaching model. Includes BBB data, FDA device status, and dietitian oversight details.
A critical look at Nutrisense CGM subscription pricing since launch, including plan changes, cost comparisons, complaint patterns, and what the evidence says about CGM value for non-diabetic users.
A detailed timeline of Sequence membership pricing, the WeightWatchers Clinic rebrand, cost complaints from verified sources, and what the current fee structure means for prospective GLP-1 members.
An independent review of Shapiro MD BBB ratings, consumer complaints, FDA status, and ingredient evidence. Includes complaint trend analysis, refund policy details, and what board-certified physicians say about the brand's hair-loss claims.
An independent look at Shed's BBB rating, consumer complaints, FDA warning letters, and LegitScript status for compounded GLP-1 products. Updated with primary-source citations throughout.
An independent review of Shed's LegitScript status, pharmacy accreditation, compounded semaglutide safety, and FDA oversight. Includes citations to FDA, LegitScript, and primary medical sources.
An independent look at Superpower's subscription fees, how pricing has shifted since launch, what the concierge lab-plus-GLP-1 model delivers for the cost, and whether the platform is legitimate.
An independent review of Talkspace's medical leadership, clinician credentialing process, regulatory standing, and complaint history. prepared by the HealthRX.com Editorial Team.
A detailed, independent look at Thirty Madison's pricing history across Keeps, Cove, Facet, and Picnic. Includes cost comparisons, complaint data, and regulatory context.
An independent review of Thrive Causemetics' LegitScript status, BBB accreditation, FDA compliance, and consumer complaint history. Find out if Thrive Causemetics is a legitimate brand before you buy.
A critical, evidence-based look at Thrive Causemetics pricing history, price changes over time, legitimacy questions, and consumer complaints. prepared by the HealthRX.com Editorial Team.
An independent, evidence-based review of Viome's LegitScript certification status, FDA regulatory standing, BBB rating, and consumer complaint history. Updated 2025.
A detailed, independent review of Winona's menopause HRT pricing history, cost trajectory, legitimacy, complaints, and how its cash-pay telehealth model compares to alternatives. prepared by the HealthRX.com Editorial Team.
A critical, data-driven look at ZOE's subscription pricing history, membership cost changes, CGM kit fees, and what independent watchdog sources say about the program's value and legitimacy.
An evidence-based breakdown of who should consider Viome microbiome testing, what the science supports, where the evidence falls short, and how Viome compares to alternatives for gut health, metabolic optimization, and chronic disease management.
A clinical guide to Aetna (CVS Health) coverage for Vyleesi (bremelanotide), including prior authorization criteria, step therapy requirements, formulary tier, appeal strategies, and manufacturer savings options.
Bremelanotide (Vyleesi) is not approved for children under 12. This guide covers FDA pediatric labeling, melanocortin receptor physiology in children, and what to do if accidental exposure occurs.
A guide to bremelanotide (Vyleesi) safety during pregnancy and breastfeeding, covering mechanism of action, FDA labeling, reproductive toxicology data, and practical clinical guidance.
A clinical-depth review of bremelanotide (Vyleesi) and cancer risk signals, covering FDA labeling, RECONNECT trial data, melanoma warnings, and practical prescribing guidance for premenopausal women with HSDD.
A GRADE-level appraisal of bremelanotide (Vyleesi) for hypoactive sexual desire disorder in premenopausal women, including RECONNECT trial data, effect sizes, safety profile, and prescribing guidance.
A week-by-week guide to bremelanotide (Vyleesi) covering what to expect in the first month: dosing, side effects, efficacy timelines, and clinical trial data.
A clinician-level guide to the bremelanotide (Vyleesi) pre-surgery hold window, covering FDA labeling, cardiovascular pharmacology, anesthesia interactions, and practical perioperative management protocols.
A clinician-level review of how bremelanotide (Vyleesi) affects sexual desire, arousal, and distress in premenopausal women with HSDD, based on RECONNECT trial data and FDA-approved prescribing information.
A fact-checked timeline of Khloé Kardashian's public weight-loss statements, the limits of appearance-based GLP-1 claims, and what semaglutide trials actually show.
A thorough clinical guide to tadalafil (Cialis) dosing in children under 12, covering FDA-approved indications, pulmonary arterial hypertension dosing, off-label uses, safety data, and monitoring requirements.
A guide to tadalafil dosing, safety, and drug interactions in transplant recipients, people living with HIV, older adults, and other special populations. Includes trial data, FDA label guidance, and clinical decision frameworks.
A complete guide to UnitedHealthcare coverage for Cialis (tadalafil), including formulary tier, prior authorization criteria, step therapy requirements, appeal steps, and cash-pay alternatives.
A guide to tadalafil dosing for men aged 18-29, covering on-demand vs. Daily regimens, fertility considerations, safety data, and how to talk to your prescriber.
A guide to tadalafil safety in men aged 18 to 29, covering cardiovascular risks, fertility effects, drug interactions, daily vs. On-demand dosing, and when to see a doctor.
A clinician-focused guide to CJC-1295 (modified GRF) dosing adjustments in hepatic impairment, covering pharmacokinetics, GH axis physiology, safety monitoring, and evidence-based dose modification strategies.
A comparison of compounded CJC-1295 (modified GRF 1-29) versus branded growth hormone secretagogue formulations, covering pharmacokinetics, dosing, regulatory status, purity data, and clinical evidence from Teichman et al. And related trials.
Evidence-based guidance on adjusting CJC-1295 (modified GRF) dosing schedules across time zones, including jet-lag pharmacology, storage during travel, and dose-timing decision frameworks, with clear notes on where evidence ends and individualized clinical judgment begins.
A clinical-grade guide to aromatase inhibitor pharmacology, prescribing, billing codes, and prior-authorization strategies for anastrozole, letrozole, and exemestane. Written for prescribers and dispensing pharmacists.
A clinician-level review of DPP-4 inhibitor pharmacology, drug-drug interactions, dosing, and safety, with a full DDI table for sitagliptin, saxagliptin, alogliptin, and linagliptin.
A prescriber-level guide to choosing between sitagliptin, saxagliptin, alogliptin, linagliptin, and trelagliptin based on renal function, cardiac history, drug interactions, and cost.
A prescriber-level monograph covering the GHRH analog drug class: mechanism, pharmacokinetics, approved agents, clinical evidence, dosing protocols, safety, and monitoring for sermorelin, tesamorelin, and related compounds.
A prescriber-level guide to managing adverse events from GIP/GLP-1 dual agonists (tirzepatide), covering nausea, pancreatitis, gastroparesis, hypoglycemia, and injection-site reactions with dose titration protocols and monitoring schedules.
A prescriber-level guide to billing codes, prior authorization strategy, step therapy, and appeal tactics for tirzepatide and the GIP/GLP-1 dual agonist class. Includes real trial data, dose thresholds, and ICD-10 documentation requirements.
A clinician-level guide to tirzepatide titration schedules, dose-escalation pacing, GI tolerability management, and evidence-based tapering strategies for GIP/GLP-1 dual agonists.
A prescriber-level guide to GIP/GLP-1 dual agonists covering mechanism, agent selection, dosing, trial data, and clinical decision-making for weight loss, T2D, sleep apnea, and HFpEF.
A complete MD/PharmD-level guide to billing codes, prior authorization strategies, and prescribing essentials for GLP-1/GIP/glucagon triple agonists including retatrutide. Includes ICD-10, CPT, and appeal templates.
A prescriber-level monograph covering the pharmacology, clinical trial data, dosing considerations, and safety profile of GLP-1/GIP/glucagon triple agonists, with a focus on retatrutide and emerging agents in this drug class.
A prescriber- and pharmacist-level guide to GLP-1 receptor agonist drug classes, dosing, prior authorization strategy, step-therapy requirements, and appeals, with primary-source citations throughout.
A clinician-level guide to the GLP-1 receptor agonist drug class, including baseline workup, ongoing monitoring, dose titration, adverse-effect management, and cardiovascular outcome data.
A clinical-level guide to GLP-1 receptor agonist titration schedules, tapering protocols, dose adjustments for tolerability, and restart strategies, written for prescribers and dispensing pharmacists.
A clinician-level review of melanocortin receptor agonists, pharmacology, prototype bremelanotide (PT-141), dosing, safety, and special-populations guidance for prescribers and pharmacists.
A physician- and pharmacist-level review of NAD precursor drugs (NMN, NR, niacin), including evidence-based titration schedules, tapering protocols, dosing algorithms, and safety monitoring parameters.
A clinician-level guide to managing adverse events with PCSK9 inhibitors (evolocumab, alirocumab, inclisiran), covering injection-site reactions, musculoskeletal complaints, neurocognitive concerns, and step-by-step protocols for FH and post-ACS patients.
A complete prescriber-level guide to PCSK9 inhibitor drug classes, FDA-approved agents, clinical evidence, prescribing criteria, and step-by-step prior authorization strategies for evolocumab and alirocumab.
A complete drug-drug interaction table for PCSK9 inhibitors (evolocumab, alirocumab, inclisiran), plus class pharmacology, dosing, and prescribing guidance for FH and post-ACS patients.
A clinician-level guide to PCSK9 inhibitor drug class review, dosing titration, tapering strategies, and prescribing algorithms for FH and post-ACS patients, prepared by the HealthRX.com Editorial Team.
A clinician-level guide to recognizing, grading, and managing adverse events from PDE5 inhibitors (sildenafil, tadalafil, vardenafil, avanafil) across ED, BPH, and pulmonary hypertension indications, with prescribing thresholds, drug interaction tables, and monitoring protocols.
A prescriber-level review of micronized progesterone versus synthetic progestins across special populations: pregnancy, menopause, cardiovascular risk, breast cancer history, liver disease, and more. Includes dosing, trial data, and guideline recommendations.